- Home
- COHU vs IRWD Comparison
COHU vs IRWD Comparison
Compare COHU & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHU
- IRWD
- Stock Information
- Founded
- COHU 1947
- IRWD 1998
- Country
- COHU United States
- IRWD United States
- Employees
- COHU N/A
- IRWD N/A
- Industry
- COHU Electrical Products
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- COHU Industrials
- IRWD Health Care
- Exchange
- COHU Nasdaq
- IRWD Nasdaq
- Market Cap
- COHU N/A
- IRWD 150.9M
- IPO Year
- COHU N/A
- IRWD 2010
- Fundamental
- Price
- COHU $16.39
- IRWD $0.73
- Analyst Decision
- COHU Buy
- IRWD Buy
- Analyst Count
- COHU 7
- IRWD 5
- Target Price
- COHU $29.50
- IRWD $4.94
- AVG Volume (30 Days)
- COHU 559.1K
- IRWD 4.2M
- Earning Date
- COHU 05-01-2025
- IRWD 05-07-2025
- Dividend Yield
- COHU N/A
- IRWD N/A
- EPS Growth
- COHU N/A
- IRWD N/A
- EPS
- COHU N/A
- IRWD N/A
- Revenue
- COHU $390,962,000.00
- IRWD $317,676,000.00
- Revenue This Year
- COHU $11.41
- IRWD N/A
- Revenue Next Year
- COHU $17.10
- IRWD N/A
- P/E Ratio
- COHU N/A
- IRWD N/A
- Revenue Growth
- COHU N/A
- IRWD N/A
- 52 Week Low
- COHU $12.57
- IRWD $0.59
- 52 Week High
- COHU $36.60
- IRWD $8.23
- Technical
- Relative Strength Index (RSI)
- COHU 52.33
- IRWD 29.40
- Support Level
- COHU $15.34
- IRWD $0.88
- Resistance Level
- COHU $17.26
- IRWD $0.98
- Average True Range (ATR)
- COHU 0.67
- IRWD 0.10
- MACD
- COHU 0.13
- IRWD 0.02
- Stochastic Oscillator
- COHU 69.72
- IRWD 11.74
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.